TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00005648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine with R115777
Description: R115777 200 mg, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine with Placebo
Description: Placebo, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
Study: NCT01175109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib + LBH589
Description: Escalating doses of imatinib and LBH589 will be administered.
Study: NCT01425203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: boceprevir 200-mg capsules, 800 mg 3 times a day (TID), orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: boceprevir 200-mg capsules, 800 mg 3 times a day (TID), orally (PO)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: boceprevir-matched placebo four 200-mg capsules PO TID.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b
Description: peginterferon alfa-2b 1.5 μg/kg/wk subcutaneously (SC)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: peginterferon alfa-2b
Description: peginterferon alfa-2b 1.5 μg/kg/wk subcutaneously (SC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b
Description: peginterferon alfa-2b 1.5 μg/kg/wk subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: ribavirin (weight-based dosing) 800 to 1400 mg/day PO divided twice daily dose (BID).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: ribavirin (weight-based dosing) 800 to 1400 mg/day PO divided twice daily dose (BID).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: ribavirin (weight-based dosing) 800 to 1400 mg/day PO divided twice daily dose (BID).
Study: NCT02419287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Study: NCT01391507

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % sodium chloride
Description: Monthly intravenous injection for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COR-1
Description: Monthly intravenous injection for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COR-1
Description: Monthly intravenous injection for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COR-1
Description: Monthly intravenous injection for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy for heart failure
Description: All patients will continue to receive standard therapy for heart failure (ie, in accordance with guidelines) throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy for heart failure
Description: All patients will continue to receive standard therapy for heart failure (ie, in accordance with guidelines) throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy for heart failure
Description: All patients will continue to receive standard therapy for heart failure (ie, in accordance with guidelines) throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy for heart failure
Description: All patients will continue to receive standard therapy for heart failure (ie, in accordance with guidelines) throughout the study.
Study: NCT03700307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Description: Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Description: Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice.
Study: NCT01456676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib + LDE225
Description: Nilotinib is an aminopyrimidine ATP-competitive inhibitor of the protein tyrosine kinaseactivity of BCR-ABL.
Study: NCT03094871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACE-PC
Study: NCT01780025

Intervention type: BEHAVIORAL
Intervention: Auditory evoked potentials and audiometry

Intervention type: BEHAVIORAL
Intervention: Auditory evoked potentials
Description: Different protocols for audiometry and auditory evoked potentials
Study: NCT04163068

Intervention type: OTHER
Intervention: Interview
Description: The interview will last approximately 45 minutes, will be audio-recorded, transcribed, and analysed
Study: NCT00283595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Growth Hormone
Description: Dosage increased in steps for first four weeks. Self injection qd x 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Recombinant Human Growth Hormone
Description: Administered as Arm 1, rHGH active Injection qd x 12 weeks Dosage increase over four weeks
Study: NCT00857727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be dissolved in saline. An initial loading dose of 1.0 mg/kg given over 10 minutes followed by a continuous infusion at 0.4-0.7 mg/kg/hour. Beginning approximately one hour prior to end of surgery and continuing for one hour of recovery in the PACU and the PICU. This, the maximum dose for any one patient will be 2.4 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Given by a continuous infusion
Study: NCT02961556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJG555
Description: Participants will receive 1 to 6 sachets daily per participants' age and conditions.
Study: NCT04103437

Intervention type: DIAGNOSTIC_TEST
Intervention: Maximal incremental running test
Description: Maximal incremental running test with measures of metabolic, spatio-temporal parameters and video recording with camera in the frontal plane.~video recording of frontal view, metabolic and spatio-temporal measures of three (self-selected speed, + and - 20 percentage of self-selected speed) 6 minutes running test monthly (12 months) follow-up questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolic and movement analysis of running
Description: Running analysis of three six minutes running test (self-selected speed, + and - 20% of the self-selected speed) by video recording with camera in the frontal plane, and acquisition of the metabolic and spatio-temporal parameters

Intervention type: OTHER
Intervention: Questionnaires
Description: Monthly follow-up questionnaire (12 months) about training habits and injuries
Study: NCT00813423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study: NCT00845728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 µg
Description: Indacaterol 150 µg o.d. delivered via SDDPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 µg o.d. delivered via handihaler®
Study: NCT01716910

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Combination of Lactobacillus acidophilus NCFM and cellobiose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Combination of Lactobacillus acidophilus NCFM and cellobiose
Study: NCT01803360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neridronate
Description: Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment
Study: NCT04418700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breath Stacking
Description: The patients will perform the maneuver through successive inspiratory efforts for 20 s. Subsequently, the expiratory branch will be unobstructed to allow expiration. This maneuver will be repeated 5 times in each series, with intervals of 30 seconds between them. The technique will be performed with the trunk inclined 30º in relation to the horizontal plane, in 3 series, with interval of 2 min completing 15 min of therapy.
Study: NCT01338415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Oral dispersible tablet administered as 2mg/kg two (b.i.d.) or three (t.i.d.) times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Oral dispersible tablet administered as 2mg/kg two (b.i.d.) or three (t.i.d.) times per day
Study: NCT02206646

Intervention type: DRUG
Intervention: Metalyse
Study: NCT01829256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist telehealth intervention
Description: A tailored intervention with medication management and behavioral components. The behavioral modules may include, diet, exercise, weight, tobacco use, medication management, side effects, diabetes education, DKD/ HTN/ CVD risk and knowledge.Based on the patient's responses to a series of questions, there will be a provision of tailored feedback to reinforce evidence-based behavior for disease and lifestyle management.
Study: NCT00941876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated Referral
Description: Seven key steps carried out by CTC and FP staff to encourage completion of FP referral by CTC.
Study: NCT00798746

Intervention type: BEHAVIORAL
Intervention: Telephone Questionnaire
Description: Ten questions regarding symptoms of reflux

Intervention type: BEHAVIORAL
Intervention: Telephone Questionnaire
Description: Ten questions regarding symptoms of reflux
Study: NCT04451954

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent RIV with H3 strain 1
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent RIV with H3 strain 1 and adjuvant
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent RIV with H3 strain 2
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent RIV with H3 strain 2 and adjuvant
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent RIV with 2018-2019 NH H3 strain
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent RIV with 2018-2019 NH H3 strain
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study: NCT03529773

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01558362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123I-CMICE-013
Description: 2 intravenous doses of drug will be given one week apart. Doses will be equivalent to 1 rest dose and 1 stress dose. Serial nuclear imaging will follow dose injections.
Study: NCT01496066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAL (Light Adjustable Lens) and Light Deliver Device (LDD)
Description: LAL implanted and adjusted with LDD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monofocal control IOL
Description: Commercially available monofocal intraocular lens (IOL)
Study: NCT02117765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Study: NCT03662425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: It's a two-week treatment trial.Subjects self-administer intranasal study drug twice daily; before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of OT spray containing approximately 24 international units of OT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: It's a two-week treatment trial. Subjects self-administer intranasal study drug twice daily; before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of saline spray containing approximately 24 international units of saline
Study: NCT03237065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside/ferric derisomaltose
Description: Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: Ferric carboxymaltose (Injectafer®; 50 mg/mL) was the comparator in this trial. The dose of ferric carboxymaltose for the individual subject was 750 mg, infused over at least 15 minutes at baseline and on day 7 (cumulative dose: 1500 mg).
Study: NCT00793650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Escalating doses of bortezomib 1.0, 1.3, or 1.6 mg/m2 in Arm A and Arm B.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Escalating doses of bortezomib 1.0, 1.3, or 1.6 mg/m2 in Arm A and Arm B.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: All patients received melphalan (100 mg/m\^2/day × 2; days~-3 and -2), for a total dose of 200 mg/m\^2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: All patients received melphalan (100 mg/m\^2/day × 2; days~-3 and -2), for a total dose of 200 mg/m\^2.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous PBSC Transplant
Description: Day 0 consists of the stem cell infusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous PBSC Transplant
Description: Day 0 consists of the stem cell infusion.
Study: NCT04032990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biostim-5 transcutaneous spinal stimulator
Description: Safety and feasibility will be monitored during transcutaneous spinal stimulation in children with spinal cord injury
Study: NCT03589378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEAF
Description: PEAF that is therapeutic plasma exchange (TPE) with 20ml/kg/d Fresh frozen plasma (Blood pump: 120ml/min, replacement pump 20ml/kg/min, dialysate pump 0ml/kg/min, waste pump 20ml/kg/min, plasma exchange 1 hour) plus plasma filtration adsorption (PFA ) with acute multitherapeutic system( AMPLYA™ ITALY) ≥30ml/min lasting 15 hours plus High volume plasma diafiltration (HVPDF) with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) Blood pump: 120ml/min, replacement fluid pump 2000ml/h, dialysate pump 2000ml/h, waste pump 4000ml/h,and with high-volume plasma diafiltration for 15 hours）in the first 3 days. the treatment after three days later is same as the control group.
Study: NCT03524339

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.
Study: NCT00772668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered intravenously during induction and maintenance therapy per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Administered intravenously per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally (PO) per protocol.
Study: NCT00864955

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVA and UVB irradiation
Description: * 4 cutaneous biopsies for Ex-vivo irradiation~* Determination of the minimal erythemic dose of UVA and UVB for each volunteer

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVA and UVB irradiation
Description: * 4 cutaneous biopsies for Ex-vivo irradiation~* Determination of the minimal erythemic dose of UVA and UVB for each volunteer
Study: NCT01331356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: One injection of botulinum toxin type A in the ganglion Impar in patients with chronic proctalgia
Study: NCT04114435

Intervention type: OTHER
Intervention: Echocardiography
Description: Diagnostic test which uses ultrasound waves to make images of the heart chambers, valves and surrounding structures

Intervention type: OTHER
Intervention: Echocardiography
Description: Diagnostic test which uses ultrasound waves to make images of the heart chambers, valves and surrounding structures

Intervention type: OTHER
Intervention: Echocardiography
Description: Diagnostic test which uses ultrasound waves to make images of the heart chambers, valves and surrounding structures
Study: NCT04146610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: an antibody drug conjugate
Description: Multiple dose grouping
Study: NCT03703973

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychology test
Description: We do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test 1 day before (baseline) and 1 week,3 months,1 year and 3 years after surgery without safety issue.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychology test
Description: We do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test 1 day before (baseline) and 1 week,3 months,1 year and 3 years after surgery without safety issue.
Study: NCT03324997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restylane Silk
Description: Restylane Silk is a temporary hyaluronic acid filler currently approved for the lips and fine lines around the mouth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline as placebo

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Optical Coherence Tomography
Description: An FDA-cleared non-invasive imaging device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: An FDA-cleared non-invasive imaging device
Study: NCT04492683

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DBV1605
Description: Ready-to-use atopy patch test for diagnostic use containing 2 distinct patches:~* One active patch containing a dry deposit of 180 μg of cow's milk proteins~* One control patch with the same design as the active patch but devoid of any formulation.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DBV1605
Description: Ready-to-use atopy patch test for diagnostic use containing 2 distinct patches:~* One active patch containing a dry deposit of 180 μg of cow's milk proteins~* One control patch with the same design as the active patch but devoid of any formulation.